At a glance
ClinicalIndex Comparison RecordPhase 2Active· 30 enrolled
Drug / intervention
Epacadostat +1 moredrug
Likely dose
Epacadostat 100mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase II Study of Epacadostat (INCB024360) in Combination With Pembrolizumab in Patients With Locally Advanced/Metastatic Sarcoma
In Brief
A Phase 2 clinical trial evaluating Epacadostat and Pembrolizumab for Sarcoma. Active but no longer recruiting, targeting 30 participants across 1 site.
Detailed Summary
The purpose of this study is to test any good and bad effects of the combination therapy of epacadostat and pembrolizumab and to determine how well the combination therapy works in the treatment of patients with sarcoma.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSarcoma
CountriesUnited States
CollaboratorsIncyte Corporation, Merck Sharp & Dohme LLC, M.D. Anderson Cancer Center
Timeline
Phase 2Active
2018201920202021202220232024202520262027
Enrollment StartJan 2018
First PostedJan 2018
Primary CompletionSep 2024
TodayJul 2026
Study CompletionJan 2027
First PostedJan 29, 2018
Enrollment StartJan 23, 2018
Primary CompletionSep 9, 2024
Study CompletionJan 1, 2027
TodayJul 2, 2026
Enrollment to primary: 6.6 yearsPosted 8.4 years ago
Interventions
Epacadostatdrug
100mg bid days 1-21
Pembrolizumabdrug
200mg/dose Day 1, Q 3 weeks